Dylan Barbera received his bachelors in Biochemistry and Molecular Biology with a minor in Microbiology from The Pennsylvania State University. He received his Master's of Science from Mount St. Mary's University in Biotechnology and Management. Dylan began his career in NGS in 2015 and joined QIAGEN in 2016 as a Quality Control Scientist. He currently serves as a Global Product Manager for QIAGEN's portfolio of Microbiology and Whole Genome Sequencing NGS products.

Shu Boles holds a PhD in developmental biology from Washington University in St. Louis and did her postdoctoral training at UC San Diego. She also holds an MBA from UC San Diego – Rady School of Management. Shu has extensive experience in next-generation sequencing in research applications, especially cancer research, and clinical oncology. In 2022, Shu joined QIAGEN as Director of Genomics Strategic Marketing.

Brian is Senior Director of Product Management for QIAGEN’s UNGS portfolio. He received his MS from Georgetown University in Biochemistry and Molecular Biology and was a research assistant at Eunice Shriver NICHD. For over a decade, he has worked in genomics at some of the earliest NGS testing companies at EdgeBio and Personalis and launching the first commercial NGS products at Pillar Biosciences. Brian first joined QIAGEN in 2015.

Peter Hesse, MBA, is a biologist with more than 20 years of professional experience. He has held management positions in life sciences, healthcare and consultancy and has experience in product management, strategic and commercial marketing, as well as business strategy. Peter joined QIAGEN in 2011 and has since held different management roles with steadily growing responsibilities. In September 2021, he was appointed Vice President Head of Genomics.

Jonas Korlach is one of the founders of PacBio. He co-invented the SMRT technology with Dr. Stephen Turner when the two were graduate students at Cornell University. He has held multiple positions at PacBio, including leading the molecular biology division, Principal Scientist and Chief Scientific Officer. Dr. Korlach is the recipient of multiple grants, an inventor on over 70 issued U.S. and international patents. He’s an author of over 100 scientific studies on the principles and applications of SMRT technology, including publications in Nature, Science and PNAS. In 2013, Dr. Korlach was honored by the Obama White House as an Immigrant Innovator “Champion of Change.” He received both his PhD and his MS degrees in Biochemistry, Molecular and Cell Biology from Cornell, and received MS and BA degrees in Biological Sciences from Humboldt University in Berlin, Germany.

Shawn has over 20 years of experience in genomic applications development and technology optimization, as well as operational management of research, development, and clinical testing programs. Prior to joining Element, Shawn was Chief Scientific Officer at Discovery Life Sciences and a faculty investigator at the HudsonAlpha Institute for Biotechnology. While at HudsonAlpha, Shawn developed a comprehensive genomics facility that has supported more than 5,200 projects from locations around the world. His laboratory raised more than $150M in extramural funding, culminating in the largest financial transaction in HudsonAlpha’s history when the assets of his research group were sold to Discovery Life Sciences. Before HudsonAlpha, Shawn was a faculty member at Vanderbilt University Medical Center in the Department of Biomedical Informatics and the Department of Molecular Physiology and Biophysics. He is an author or co-author of more than 200 peer-reviewed publications with over 45,000 citations.

Dr. Marina Wiklander is Regional Marketing Manager for Molecular Diagnostics in Oncology and Translational Genomics at QIAGEN. She earned her PhD in experimental pathology from Uppsala University, specializing in research on the epigenetic study of multiple myeloma.